MINT-CANDESARTAN TABLET

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

CANDESARTAN CILEXETIL

Beszerezhető a:

MINT PHARMACEUTICALS INC

ATC-kód:

C09CA06

INN (nemzetközi neve):

CANDESARTAN

Adagolás:

4MG

Gyógyszerészeti forma:

TABLET

Összetétel:

CANDESARTAN CILEXETIL 4MG

Az alkalmazás módja:

ORAL

db csomag:

30/100/1000

Recept típusa:

Prescription

Terápiás terület:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Termék összefoglaló:

Active ingredient group (AIG) number: 0135220001; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2018-06-05

Termékjellemzők

MINT-CANDESARTAN Product Monograph
Page 1 of 34
PRODUCT MONOGRAPH
PR
MINT-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
Mint Pharmaceuticals Inc., DATE OF REVISION:
6575 Davand Drive
November 29, 2022
Mississauga, Ontario
L5T 2M3
Submission
Control No: 265629
MINT-CANDESARTAN Product Monograph
Page 2 of 34
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...........................................................
3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL
USE................................................................................
3
CONTRAINDICATIONS
....................................................................................................
3
WARNINGS AND PRECAUTIONS
...................................................................................
4
ADVERSE REACTIONS
....................................................................................................
8
DRUG
INTERACTIONS....................................................................................................13
DOSAGE AND
ADMINISTRATION.................................................................................14
OVERDOSAGE
.................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
................................................................17
STORAGE AND
STABILITY............................................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................20
PART II: SCIENTIFIC
INFORMATION................................................................................21
PHARMACEUTICAL
INFORMATION.............................................................................21
CLINICAL TRIALS
..........................................................................................